Treatment details
Animal . | Sex . | Age, mos . | Weight, kg . | Vector . | Vector dose, vp/kg . |
|---|---|---|---|---|---|
| Dog A | Female | 16 | 10.6 | HD-HNF-cFVIII | 5.00 × 1011 |
| Dog B | Male | 84 | 14.2 | HD-HNF-cFVIII | 1.25 × 1012 |
| Dog C | Female | 22 | 8.9 | HD-HNF-cFVIII | 1.25 × 1012 |
| Dog D | Male | 16 | 10.8 | HD-CMV-cFVIII | 2.00 × 1012 |
Animal . | Sex . | Age, mos . | Weight, kg . | Vector . | Vector dose, vp/kg . |
|---|---|---|---|---|---|
| Dog A | Female | 16 | 10.6 | HD-HNF-cFVIII | 5.00 × 1011 |
| Dog B | Male | 84 | 14.2 | HD-HNF-cFVIII | 1.25 × 1012 |
| Dog C | Female | 22 | 8.9 | HD-HNF-cFVIII | 1.25 × 1012 |
| Dog D | Male | 16 | 10.8 | HD-CMV-cFVIII | 2.00 × 1012 |
Four hemophilic dogs were administered HD-Ad vectors via cephalic vein infusion. A total of 10 mL was infused into each animal at a rate of approximately 2 mL per minute. Each dog had been treated with canine cryoprecipitate to treat a bleeding episode at least once prior to entry into the study.